C E Patterson

Summary

Publications

  1. ncbi request reprint A 6-month open-label study of the effectiveness and tolerability of galantamine in patients with Alzheimer's disease
    C E Patterson
    Department of Geriatric Medicine, Whitla Medical Building, Queen s University Belfast, Belfast, UK
    Int J Clin Pract 58:144-8. 2004
  2. doi request reprint Effect of apolipoprotein E and butyrylcholinesterase genotypes on cognitive response to cholinesterase inhibitor treatment at different stages of Alzheimer's disease
    C E Patterson
    Belfast Health and Social Care Trust, Belfast, UK
    Pharmacogenomics J 11:444-50. 2011

Detail Information

Publications2

  1. ncbi request reprint A 6-month open-label study of the effectiveness and tolerability of galantamine in patients with Alzheimer's disease
    C E Patterson
    Department of Geriatric Medicine, Whitla Medical Building, Queen s University Belfast, Belfast, UK
    Int J Clin Pract 58:144-8. 2004
    ..This naturalistic study confirms clinical trial data, which shows galantamine improves cognition and behavioural symptoms and is overall well tolerated...
  2. doi request reprint Effect of apolipoprotein E and butyrylcholinesterase genotypes on cognitive response to cholinesterase inhibitor treatment at different stages of Alzheimer's disease
    C E Patterson
    Belfast Health and Social Care Trust, Belfast, UK
    Pharmacogenomics J 11:444-50. 2011
    ..01). In moderate-to-severe AD (MMSE ≤15), presence of the BCHE-K variant was associated with late response to cholinesterase inhibitor treatment (P=0.02). Testing for APOE and BCHE genotypes may be useful in therapeutic decision making...